Projects
CD3 - the Centre for Drug Design and Discovery – discovering new drugs based on innovative research KU Leuven
Het Centre for Drug Design and Discovery (CD3) is een drug discovery centrum en investeringsfonds dat focust op de transformatie van innovatief basisonderzoek naar klinische toepassing. CD3’s activiteiten zijn steeds gebaseerd op een samenwerkingsmodel met academische onderzoeksgroepen en biotech/pharma partners om samen nieuwe geneesmiddelen te ontwikkelen. Het ervaren drug discovery team van CD3 investeert in bedrijven en in vroege drug ...
Data Integration in Drug-Target Interaction Prediction for Drug Discovery and Drug Repositioning KU Leuven
Approved drugs have favorite or validated pharmacokinetic properties and toxicological profiles, and the repositioning of existing drugs for new indications can potentially avoid expensive costs associated with early-stage testing of the hit compounds. In recent years technological advances in virtual screening methodologies have allowed medicinal chemists to rapidly screen drug library for therapeutic activity against new biomolecular ...
Neuro-TARGET : integrated platform for target identification, validation and drug discovery with applications for neurodegenerative diseases. Vrije Universiteit Brussel
Zebrafish platform for neuroactive drug discovery and safety assessment KU Leuven
Targeting cannabinoid receptor signaling for drug discovery and characterization: A focus on CB1 and CB2 cannabinoid receptors and GIRK1/GIRK2 potassium channels KU Leuven
In cannabinoid (CB) receptor signaling, CB1 and CB2 receptors and G protein-coupled inwardly rectifying potassium (GIRK1/GIRK2) channels have attracted considerable attention from scientists in investigating their therapeutic potential for diverse diseases, especially in neurological diseases.
CB1 and CB2 receptors, the G protein-coupled receptors (GPCRs) and members of the endocannabinoid system, are pleiotropic signaling molecules and ...
NEOMODELS: Flatworms as new model organisms for stem cell biology, carcinogenesisand drug discovery (Type 3) Ghent University
In this project we will try to validate flatworms as new model organisms and to get a proof of concept of their applicability as a preclinical model systems. First you will develop an in vivo stem cell proliferation assay. This assay will be used specifically to test the stem cell dynamics under the influence of carcinogens and anti-cancer drugs. One will begin testing of well-known agents in order to validate the assay. The central nervous ...
Drug discovery and gene therapy KU Leuven
This valorization program covers an integrated strategy for disease model development, drug discovery and gene therapy approaches. The program is actively exploiting viral vector technology for the development and validation of screening platforms and model systems for drug discovery and gene therapy. The resulting platforms are subsequently advanced in dedicated valorization trajectories. The viral vector technology and services, developed ...
Next Generation Screening in Quantitative Biology & Drug Discovery KU Leuven
In this proposal we outline a state-of-the-art platform that would be among the first in Europe to combine the best in automated microscopy with advanced cell culture robotics capable of automated isolation, expansion and differentiation of mammalian and human cells, including iPSC. The platform will be unique in Flanders and will allow running quantitative image-based screens as well as screens for disease phenotypes using conventional cell ...
From target identification to drug discovery KU Leuven
Preclinical drug discovery from target validation, through assay development and biological profiling of novel hit and lead compounds. As such, we address different research areas including (1) HIV treatment and (functional) cure, (2) leukemia and in particular Mixed Lineage Leukemia, (3) Cystic Fibrosis and (4) Rett and MeCP2 Duplication syndrome. In collaboration with medicinal chemists and structural biologists we develop IP in these areas ...